✦ LIBER ✦

Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole

✍ Scribed by Mario Valenzano Menada; Sergio Costantini; Melita Moioli; Stefano Bogliolo; Andrea Papadia; Simone Ferrero; Maria Cristina Dugnani

Book ID: 113507053
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 250 KB
Volume: 17
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2008.05.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness of switching from adjuvant

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

✍ Walter Jonat; Michael Gnant; Francesco Boccardo; Manfred Kaufmann; Alessandra Ru 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 101 KB

Cost-Effectiveness of Letrozole Versus T

Cost-Effectiveness of Letrozole Versus Tamoxifen as Initial Adjuvant Therapy in Hormone Receptor–Positive Postmenopausal Women with Early-Stage Breast Cancer

✍ Thomas E. Delea; Jon Karnon; Oleg Sofrygin; Simu K. Thomas; Natalie L. Papo; Vic 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 194 KB

CN3 HEALTH ECONOMIC EVALUATION BASED ON

CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

✍ K Moeremans; L Annemans 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Cost-effectiveness of letrozole versus t

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective

✍ Thomas E. Delea; Khalid El-Ouagari; Jonathan Karnon; Oleg Sofrygin 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 301 KB

Histopathological assessment of anastroz

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

✍ Masafumi Kurosumi; Yuichi Takatsuka; Toru Watanabe; Shigeru Imoto; Hideo Inaji; 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 357 KB

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br